Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
复制标题
儿科临床前测试联盟在骨肉瘤临床前模型中艾日布林的剂量反应效应。
DOI:
10.1002/pbc.28606
复制
发表时间:
2020-10
影响因子:
3.2
通讯作者:
Gorlick R
中科院分区:
文献类型:
--
作者:
Gill J;Zhang W;Zhang Z;Roth M;Harrison DJ;Rowshan S;Erickson S;Gatto G;Kurmasheva R;Houghton P;Teicher B;Smith MA;Kolb EA;Gorlick R
The pediatric preclinical testing program previously demonstrated activity of eribulin in osteosarcoma patient-derived xenograft (PDX) models. The phase 2 trial in patients with relapsed osteosarcoma failed to meet response endpoints. Eribulin was evaluated in the original and an expanded set of PDX models and tested at multiple dose levels and schedules to evaluate dose-response. Maximal response was observed at the highest dose, consistent with prior results. The alternative schedule generated similar responses. We demonstrate steep dose-response for eribulin in osteosarcoma PDX models, implying that any deviation from achievement of effective concentrations may have a significant impact on activity.
登录
查看更多内容
影响因子:
11.2
作者:
Kuznetsov, G;Towle, MJ;Littlefield, BA
通讯作者:
Littlefield, BA
影响因子:
3.2
作者:
Kolb, E. Anders;Gorlick, Richard;Smith, Malcolm A.
通讯作者:
Smith, Malcolm A.
影响因子:
11.5
作者:
Goel, Sanjay;Mita, Alain C.;Takimoto, Chris H.
通讯作者:
Takimoto, Chris H.
DOI:
10.1158/1078-0432.ccr-07-5090
发表时间:
2008-07-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Neale G;Su X;Morton CL;Phelps D;Gorlick R;Lock RB;Reynolds CP;Maris JM;Friedman HS;Dome J;Khoury J;Triche TJ;Seeger RC;Gilbertson R;Khan J;Smith MA;Houghton PJ
通讯作者:
Houghton PJ
影响因子:
3.2
作者:
Isakoff, Michael S.;Goldsby, Robert;Janeway, Katherine A.
通讯作者:
Janeway, Katherine A.